600535 Tasly Pharmaceutical Group
- 12.90
- +0.60+4.88%
Tasly Pharmaceutical Group News
Tasli: Tasli's announcement on the subscription of Yongtai Biotech Convertible Bonds and some of its shareholders' shares
Asset evaluation report of Liaoning Tianshili Shenrong Health Products Co., Ltd. due to asset transfer
Tasli: Tianli's 2021 Annual Equity Distribution Implementation Notice
Tianli's 2021 Annual Equity Distribution Implementation Notice
Guoxin Securities Co., Ltd.'s 2021 Continued Supervision Opinions and Continued Supervision Summary Report on the Sale of Major Assets of Tianshili Pharmaceutical Group Co., Ltd.
Tasli: Tasli's announcement on profit and loss during the transition period for the sale of major assets
Tasili: Audit report on the sale of significant assets issued by Daxin Certified Public Accountants
Tasili: Announcement on the progress of implementation of major asset sales
Tasili: Report on the implementation of the sale of significant assets
Tasili: Announcement on the completion of the transfer of assets subject to the sale of major assets
Tasili: Announcement on the progress of implementation of major asset sales
Tasili: Announcement on the progress of implementation of major asset sales
Tasili: Significant Asset Sale Report (Draft) Summary (Revised Draft)
Tasili: Significant Asset Sale Report (Draft) (Revised Draft)
Tasili: Notice on the revision of the substantial asset sale report (draft) and its summary
Tasili: Significant Asset Sale Report (Draft)
Tasili: Significant Asset Sale Report (Draft) Summary
Tasili: An indicative announcement on the general risks of major asset sales
Tasili: The Board of Directors explains that the entities involved in this major asset sale do not have any “Interim Provisions on Strengthening the Supervision of Abnormal Stock Transactions Related to Major Asset Restructurings of Listed Companies” Artic
Tasili: Announcement on the progress of planning the sale of major assets
Analysis
Price Target
No Data
